The macular degeneration treatment market size has grown rapidly in recent years. It will grow from $9.74 billion in 2023 to $10.99 billion in 2024 at a compound annual growth rate (CAGR) of 12.8%. Historical growth can be attributed to an aging population, lifestyle changes, limited treatment options, increased awareness, and the development of healthcare infrastructure.
The macular degeneration treatment market size is expected to see rapid growth in the next few years. It will grow to $16.99 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%. The anticipated growth in the forecast period can be attributed to advancements in research, increased healthcare expenditure, rising incidence rates, personalized medicine approaches, and global efforts for vision health. Major trends expected in this period include a focus on neuroprotection and regeneration therapies, the expansion of telemedicine and remote monitoring, personalized medicine approaches, the investigation of stem cell therapies, and patient-focused initiatives for awareness and education.
The rise in retinal disorders is anticipated to drive the growth of the macular degeneration treatment market. Retinal disorders impact critical tissue and can disrupt the processing of visual information, resulting in distorted or impaired vision. According to the American Academy of Ophthalmology, by 2050, approximately 7.32 million people in the United States are projected to be affected by primary open-angle glaucoma, a collective term for a group of eye conditions. This condition is expected to be most prevalent among individuals aged 70 to 79 years (32%), women (50%), and Hispanics (50%). Hispanic men represent the largest demographic group affected. Consequently, the escalating prevalence of retinal disorders is fueling the expansion of the macular degeneration treatment market.
The increasing aging population is expected to drive the growth of the macular degeneration treatment market in the future. An aging population refers to a demographic shift characterized by a higher proportion of elderly individuals within a society or population. Macular degeneration treatment targets vision impairment in the aging population, focusing on a condition that affects the central part of the retina. For example, in October 2022, the World Health Organization projected that by 2030, 1 out of every 6 individuals globally would be 60 years old or older. During this period, the proportion of the population aged 60 and over is expected to rise from 1 billion in 2020 to 1.4 billion. Furthermore, the global population of individuals aged 60 and older is anticipated to double, reaching 2.1 billion by 2050. Therefore, the increasing aging population is a key factor driving the macular degeneration treatment market.
One prominent trend in the market for macular degeneration treatment is the advancement of cutting-edge therapies, which has garnered considerable attention. These therapies, such as gene therapy, have seen notable progress, particularly in tackling inherited retinal diseases. For example, in October 2021, Genentech, a US-based biotech firm, announced the FDA's approval of Susvimo, a new treatment for wet age-related macular degeneration (AMD). This approval represents a significant milestone as Susvimo becomes the first treatment for wet AMD to offer an alternative to the standard-of-care eye injections, which have been required as frequently as once per month over the last 15 years. Susvimo is designed to assist individuals with wet AMD in preserving their vision with as few as two treatments per year. This is accomplished through the continuous injection of medication into the eye via a refillable implant, indicating a major advancement in offering a more convenient treatment option for wet AMD patients.
Major players in the macular degeneration treatment market are focusing on innovative solutions, such as the avacincaptad pegol intravitreal solution developed for geographic atrophy, to enhance their market performance. This solution acts as a complement C5 inhibitor targeting geographic atrophy secondary to macular degeneration. For instance, in August 2023, Astellas Pharma Inc., a Japanese pharmaceutical company, received FDA approval for IZERVAY, an avacincaptad pegol intravitreal solution designed for treating geographic atrophy (GA) linked to age-related macular degeneration (AMD). In two Phase 3 clinical trials, IZERVAY, as a complement C5 inhibitor, demonstrated a significant reduction in GA progression at the 12-month primary endpoint. Notably, the solution showed a decrease in photoreceptor loss within six months of treatment, highlighting its potential impact on addressing macular degeneration.
In September 2021, Novartis, a pharmaceutical company based in Switzerland, acquired Arctos Medical for an undisclosed sum. This acquisition is anticipated to enable Novartis to develop treatments for individuals experiencing vision loss and capitalize on the promise of optogenetics as a foundation for effective therapies. Arctos Medical, located in Switzerland, specializes in creating intelligent medical devices and gene therapy strategies for eye-related diseases aimed at addressing blindness.
Major companies operating in the macular degeneration treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Panoptica, Nidec Pharma Inc., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Valeant Pharmaceuticals, Arrys Therapeutics Inc., Santen Pharmaceuticals, StemCells Inc., Aerie Pharmaceuticals Inc., BioXcel Therapeutics Inc., Regenxbio Inc., Spark Therapeutics Inc., Alimera Sciences Inc., Rxi Pharmaceuticals, Avita Therapeutics Ltd., Applied Genetic Technologies Corp. (AGTC), Cell Medica Ltd., Ophthotech Corporation, Adverum Biotechnologies Inc., Neurotech Pharmaceuticals Inc., 4D Molecular Therapeutics Inc., GenSight Biologics Inc., NanOcular Ltd., Codiak BioSciences Inc., Nightstar Therapeutics plc.
North America was the largest region in the macular degeneration treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the macular degeneration treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The main disease stages in the macular degeneration treatment market are early-stage AMD, intermediate AMD, and late-stage AMD. Early-stage AMD is characterized by changes in the macula with medium-sized drusen deposits and no impact on vision. Intermediate AMD may cause blurry or wavy vision due to large drusen or pigment changes. Late-stage AMD results in complete central vision loss. Macular degeneration treatments include wet and dry types, administered orally, via injection, or other methods. These treatments are utilized in various medical settings such as ambulatory surgical centers, ophthalmic clinics, and hospitals.
The macular degeneration treatment research report is one of a series of new reports that provides macular degeneration treatment statistics, including macular degeneration treatment industry global market size, regional shares, competitors with macular degeneration treatment shares, detailed macular degeneration treatment segments, market trends and opportunities, and any further data you may need to thrive in the macular degeneration treatment industry. This macular degeneration treatment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The macular degeneration treatment market includes revenues earned by entities by anti-angiogenic drugs, photodynamic therapy, laser therapy and low vision aids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The macular degeneration treatment market size is expected to see rapid growth in the next few years. It will grow to $16.99 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%. The anticipated growth in the forecast period can be attributed to advancements in research, increased healthcare expenditure, rising incidence rates, personalized medicine approaches, and global efforts for vision health. Major trends expected in this period include a focus on neuroprotection and regeneration therapies, the expansion of telemedicine and remote monitoring, personalized medicine approaches, the investigation of stem cell therapies, and patient-focused initiatives for awareness and education.
The rise in retinal disorders is anticipated to drive the growth of the macular degeneration treatment market. Retinal disorders impact critical tissue and can disrupt the processing of visual information, resulting in distorted or impaired vision. According to the American Academy of Ophthalmology, by 2050, approximately 7.32 million people in the United States are projected to be affected by primary open-angle glaucoma, a collective term for a group of eye conditions. This condition is expected to be most prevalent among individuals aged 70 to 79 years (32%), women (50%), and Hispanics (50%). Hispanic men represent the largest demographic group affected. Consequently, the escalating prevalence of retinal disorders is fueling the expansion of the macular degeneration treatment market.
The increasing aging population is expected to drive the growth of the macular degeneration treatment market in the future. An aging population refers to a demographic shift characterized by a higher proportion of elderly individuals within a society or population. Macular degeneration treatment targets vision impairment in the aging population, focusing on a condition that affects the central part of the retina. For example, in October 2022, the World Health Organization projected that by 2030, 1 out of every 6 individuals globally would be 60 years old or older. During this period, the proportion of the population aged 60 and over is expected to rise from 1 billion in 2020 to 1.4 billion. Furthermore, the global population of individuals aged 60 and older is anticipated to double, reaching 2.1 billion by 2050. Therefore, the increasing aging population is a key factor driving the macular degeneration treatment market.
One prominent trend in the market for macular degeneration treatment is the advancement of cutting-edge therapies, which has garnered considerable attention. These therapies, such as gene therapy, have seen notable progress, particularly in tackling inherited retinal diseases. For example, in October 2021, Genentech, a US-based biotech firm, announced the FDA's approval of Susvimo, a new treatment for wet age-related macular degeneration (AMD). This approval represents a significant milestone as Susvimo becomes the first treatment for wet AMD to offer an alternative to the standard-of-care eye injections, which have been required as frequently as once per month over the last 15 years. Susvimo is designed to assist individuals with wet AMD in preserving their vision with as few as two treatments per year. This is accomplished through the continuous injection of medication into the eye via a refillable implant, indicating a major advancement in offering a more convenient treatment option for wet AMD patients.
Major players in the macular degeneration treatment market are focusing on innovative solutions, such as the avacincaptad pegol intravitreal solution developed for geographic atrophy, to enhance their market performance. This solution acts as a complement C5 inhibitor targeting geographic atrophy secondary to macular degeneration. For instance, in August 2023, Astellas Pharma Inc., a Japanese pharmaceutical company, received FDA approval for IZERVAY, an avacincaptad pegol intravitreal solution designed for treating geographic atrophy (GA) linked to age-related macular degeneration (AMD). In two Phase 3 clinical trials, IZERVAY, as a complement C5 inhibitor, demonstrated a significant reduction in GA progression at the 12-month primary endpoint. Notably, the solution showed a decrease in photoreceptor loss within six months of treatment, highlighting its potential impact on addressing macular degeneration.
In September 2021, Novartis, a pharmaceutical company based in Switzerland, acquired Arctos Medical for an undisclosed sum. This acquisition is anticipated to enable Novartis to develop treatments for individuals experiencing vision loss and capitalize on the promise of optogenetics as a foundation for effective therapies. Arctos Medical, located in Switzerland, specializes in creating intelligent medical devices and gene therapy strategies for eye-related diseases aimed at addressing blindness.
Major companies operating in the macular degeneration treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Panoptica, Nidec Pharma Inc., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Valeant Pharmaceuticals, Arrys Therapeutics Inc., Santen Pharmaceuticals, StemCells Inc., Aerie Pharmaceuticals Inc., BioXcel Therapeutics Inc., Regenxbio Inc., Spark Therapeutics Inc., Alimera Sciences Inc., Rxi Pharmaceuticals, Avita Therapeutics Ltd., Applied Genetic Technologies Corp. (AGTC), Cell Medica Ltd., Ophthotech Corporation, Adverum Biotechnologies Inc., Neurotech Pharmaceuticals Inc., 4D Molecular Therapeutics Inc., GenSight Biologics Inc., NanOcular Ltd., Codiak BioSciences Inc., Nightstar Therapeutics plc.
North America was the largest region in the macular degeneration treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the macular degeneration treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The main disease stages in the macular degeneration treatment market are early-stage AMD, intermediate AMD, and late-stage AMD. Early-stage AMD is characterized by changes in the macula with medium-sized drusen deposits and no impact on vision. Intermediate AMD may cause blurry or wavy vision due to large drusen or pigment changes. Late-stage AMD results in complete central vision loss. Macular degeneration treatments include wet and dry types, administered orally, via injection, or other methods. These treatments are utilized in various medical settings such as ambulatory surgical centers, ophthalmic clinics, and hospitals.
The macular degeneration treatment research report is one of a series of new reports that provides macular degeneration treatment statistics, including macular degeneration treatment industry global market size, regional shares, competitors with macular degeneration treatment shares, detailed macular degeneration treatment segments, market trends and opportunities, and any further data you may need to thrive in the macular degeneration treatment industry. This macular degeneration treatment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The macular degeneration treatment market includes revenues earned by entities by anti-angiogenic drugs, photodynamic therapy, laser therapy and low vision aids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Table of Contents
1. Executive Summary2. Macular Degeneration Treatment Market Characteristics3. Macular Degeneration Treatment Market Trends and Strategies32. Global Macular Degeneration Treatment Market Competitive Benchmarking33. Global Macular Degeneration Treatment Market Competitive Dashboard34. Key Mergers and Acquisitions in the Macular Degeneration Treatment Market
4. Macular Degeneration Treatment Market - Macro Economic Scenario
5. Global Macular Degeneration Treatment Market Size and Growth
6. Macular Degeneration Treatment Market Segmentation
7. Macular Degeneration Treatment Market Regional and Country Analysis
8. Asia-Pacific Macular Degeneration Treatment Market
9. China Macular Degeneration Treatment Market
10. India Macular Degeneration Treatment Market
11. Japan Macular Degeneration Treatment Market
12. Australia Macular Degeneration Treatment Market
13. Indonesia Macular Degeneration Treatment Market
14. South Korea Macular Degeneration Treatment Market
15. Western Europe Macular Degeneration Treatment Market
16. UK Macular Degeneration Treatment Market
17. Germany Macular Degeneration Treatment Market
18. France Macular Degeneration Treatment Market
19. Italy Macular Degeneration Treatment Market
20. Spain Macular Degeneration Treatment Market
21. Eastern Europe Macular Degeneration Treatment Market
22. Russia Macular Degeneration Treatment Market
23. North America Macular Degeneration Treatment Market
24. USA Macular Degeneration Treatment Market
25. Canada Macular Degeneration Treatment Market
26. South America Macular Degeneration Treatment Market
27. Brazil Macular Degeneration Treatment Market
28. Middle East Macular Degeneration Treatment Market
29. Africa Macular Degeneration Treatment Market
30. Macular Degeneration Treatment Market Competitive Landscape and Company Profiles
31. Macular Degeneration Treatment Market Other Major and Innovative Companies
35. Macular Degeneration Treatment Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Macular Degeneration Treatment Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on macular degeneration treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for macular degeneration treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Stage of Disease: Early-Stage AMD; Intermediate AMD; Late-Stage AMD
2) By End-user: Ambulatory Surgical Centers; Ophthalmic Clinics; Hospitals
3) By Route of Administration: Oral; Injectable; Other Route of Administration
4) By Types: Wet Macular Degeneration, Dry Macular Degeneration
Key Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Allergan Inc.; Bayer AG; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Allergan Inc.
- Bayer AG
- Novartis AG
- GlaxoSmithKline plc
- Panoptica
- Nidec Pharma Inc.
- Regeneron Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Valeant Pharmaceuticals
- Arrys Therapeutics Inc.
- Santen Pharmaceuticals
- StemCells Inc.
- Aerie Pharmaceuticals Inc.
- BioXcel Therapeutics Inc.
- Regenxbio Inc.
- Spark Therapeutics Inc.
- Alimera Sciences Inc.
- Rxi Pharmaceuticals
- Avita Therapeutics Ltd.
- Applied Genetic Technologies Corp. (AGTC)
- Cell Medica Ltd.
- Ophthotech Corporation
- Adverum Biotechnologies Inc.
- Neurotech Pharmaceuticals Inc.
- 4D Molecular Therapeutics Inc.
- GenSight Biologics Inc.
- NanOcular Ltd.
- Codiak BioSciences Inc.
- Nightstar Therapeutics plc
Methodology
LOADING...
